Xencor Inc. Aktie
18,50 €
Deine Einschätzung
Xencor Inc. Aktie
Was spricht für und gegen Xencor Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Xencor Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Xencor Inc. | -0,54 % | 10,12 % | 29,37 % | -2,63 % | -3,14 % | -33,81 % | -43,09 % |
Ironwood Pharmaceuticals | 1,51 % | 6,32 % | 3,06 % | -51,03 % | -60,39 % | -60,39 % | -54,18 % |
Arrowhead Pharmaceuticals Inc. | 4,28 % | -1,60 % | -9,20 % | -28,99 % | -33,58 % | -66,10 % | -29,55 % |
Novocure Ltd | -2,19 % | 1,50 % | -2,22 % | -12,32 % | 11,17 % | -85,81 % | -77,95 % |
Kommentare
News
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Xencor Announces Proposed Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it